Clinical Trial Update: Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rituximab plus zanubrutinib and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma; efficacy and safety data n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Qingdao Central Hospital | Conditions: Overall Survival | Phase 2 | Status: UNKNOWN